The PIGQ antibody is a research tool targeting the phosphatidylinositol glycan anchor biosynthesis class Q (PIGQ) protein, a critical enzyme in the glycosylphosphatidylinositol (GPI) anchor biosynthesis pathway. GPI anchors are glycolipid structures that tether proteins to cell membranes, facilitating their localization and function. PIGQ, encoded by the PIGQ gene, acts as a subunit of the GPI GlcNAc transferase complex, which catalyzes the first step of GPI synthesis by transferring N-acetylglucosamine (GlcNAc) to phosphatidylinositol (PI). This step is essential for subsequent modifications that generate mature GPI anchors.
Antibodies against PIGQ are primarily used to study GPI biosynthesis deficiencies linked to diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and inherited GPI deficiency disorders, which manifest with neurological abnormalities, developmental delays, or hematologic defects. Researchers employ PIGQ antibodies in techniques like Western blotting, immunofluorescence, or immunohistochemistry to detect PIGQ expression levels, assess its subcellular localization, or investigate regulatory mechanisms in cellular models. Such studies help elucidate the molecular basis of GPI-related pathologies and potential therapeutic targets. Additionally, these antibodies aid in diagnosing genetic disorders caused by PIGQ mutations, enabling genotype-phenotype correlations. As GPI-anchored proteins play roles in cell signaling, immunity, and adhesion, understanding PIGQ's function through antibody-based assays contributes broadly to cell biology and clinical research.